Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISA101/ISA101b with carboplatin and paclitaxel for HPV16-positive advanced or recurrent cervical cancer
NL-OMON45132Phase 2Active, not recruiting
- Sponsor
- ISA Pharmaceuticals
- Start
- Sep 2013
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of SLP-HPV-01 in Cervical Cancer (CC) (5 arms), sponsored by ISA Pharmaceuticals. Primary endpoints: Safety and tolerability and HPV-specific immune response. Started Sep 2013; status: active, not recruiting.
02
Drugs
SLP-HPV-01
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NL-OMON45132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45132.